Skip to main content
Erschienen in: Child's Nervous System 11/2011

01.11.2011 | Original Paper

Decreased incidence of myelomeningocele at birth: effect of folic acid recommendations or prenatal diagnostics?

verfasst von: Dorte Clemmensen, Mathias Thygesen, Mikkel Mylius Rasmussen, Morten Fenger-Grøn, Olav B. Petersen, Claus Mosdal

Erschienen in: Child's Nervous System | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In Denmark, prevention to reduce the spina bifida birth rate has focused on two areas: folic acid supplementation (1997) and changes in the national ultrasonography screening programme (2004). Myelomeningocele (MMC) is the most severe malformation among the spina bifidas. Taking into consideration the potential negative effect of high-dose folic acid consumption, we found a need to look into the effectiveness of these two strategies in our complete MMC population.

Methods

All spina bifida patients born in the western part of Denmark are differentiated into proper subgroups based on MR imaging, giving us a unique chance to study a true MMC population. The total number of the group of MMC children since 1983 is 121. One hundred and eight (89%) parents answered a questionnaire.

Results

Following the changes in the prenatal ultrasonography screening programme in 2004, a significant decline of 60% live birth MMC per year was noted, incidence rate ratio (IRR) = 40% (22–73%), p = 0.3%. We found no change in MMC birth rate after introduction of folic acid supplementation, IRR = 121% (81–181%), p = 36%.

Conclusion

Our findings demonstrate no effect of folic acid recommendation due to lack of compliance among women of reproductive age in Denmark. However, we found an improved early detection rate of prenatal MMC by high-quality ultrasonography. Subsequent early termination of pregnancy has led to a significant reduction of birth rate of babies with MMC.
Literatur
1.
Zurück zum Zitat (No authors listed) (1991) Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 338:131–137 (No authors listed) (1991) Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 338:131–137
2.
Zurück zum Zitat Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, Hong SX, Correa A (1999) Prevention of neural-tube defects with folic acid in China. China-U.S. collaborative project for neural tube defect prevention. N Engl J Med 341:1485–1490PubMedCrossRef Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, Hong SX, Correa A (1999) Prevention of neural-tube defects with folic acid in China. China-U.S. collaborative project for neural tube defect prevention. N Engl J Med 341:1485–1490PubMedCrossRef
3.
Zurück zum Zitat Blencowe H, Cousens S, Modell B, Lawn J (2010) Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol 39(Suppl 1):i110–i121PubMedCrossRef Blencowe H, Cousens S, Modell B, Lawn J (2010) Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol 39(Suppl 1):i110–i121PubMedCrossRef
4.
Zurück zum Zitat Bowman RM, Boshnjaku V, McLone DG (2009) The changing incidence of myelomeningocele and its impact on pediatric neurosurgery: a review from the Children's Memorial Hospital. Childs Nerv Syst 25:801–806PubMedCrossRef Bowman RM, Boshnjaku V, McLone DG (2009) The changing incidence of myelomeningocele and its impact on pediatric neurosurgery: a review from the Children's Memorial Hospital. Childs Nerv Syst 25:801–806PubMedCrossRef
5.
Zurück zum Zitat Canfield MA, Annegers JF, Brender JD, Cooper SD, Greenberg F (1996) Hispanic origin and neural tube defects in Houston/Harris county, Texas. I. Descriptive epidemiology. Am J Epidemiol 143:1–11PubMed Canfield MA, Annegers JF, Brender JD, Cooper SD, Greenberg F (1996) Hispanic origin and neural tube defects in Houston/Harris county, Texas. I. Descriptive epidemiology. Am J Epidemiol 143:1–11PubMed
6.
Zurück zum Zitat Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bonaa KH, Spence JD, Nygard O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, Collins R, B-Vitamin Treatment Trialists' Collaboration (2010) Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 170:1622–1631PubMedCrossRef Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bonaa KH, Spence JD, Nygard O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, Collins R, B-Vitamin Treatment Trialists' Collaboration (2010) Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 170:1622–1631PubMedCrossRef
7.
Zurück zum Zitat Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, Mckeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER, Polyp Prevention Study Group (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297:2351–2359PubMedCrossRef Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, Mckeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER, Polyp Prevention Study Group (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297:2351–2359PubMedCrossRef
8.
Zurück zum Zitat Czeizel AE, Dudas I (1992) Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327:1832–1835PubMedCrossRef Czeizel AE, Dudas I (1992) Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327:1832–1835PubMedCrossRef
9.
Zurück zum Zitat De-Regil LM, Fernandez-Gaxiola AC, Dowswell T, Pena-Rosas JP (2010) Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev 10:CD007950PubMed De-Regil LM, Fernandez-Gaxiola AC, Dowswell T, Pena-Rosas JP (2010) Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev 10:CD007950PubMed
10.
Zurück zum Zitat Dommergues M, Mandelbrot L, Mahieu-Caputo D, Boudjema N, Durand-Zaleski I, ICI Group-Club de medecine foetale (2010) Termination of pregnancy following prenatal diagnosis in France: how severe are the foetal anomalies? Prenat Diagn 30:531–539PubMedCrossRef Dommergues M, Mandelbrot L, Mahieu-Caputo D, Boudjema N, Durand-Zaleski I, ICI Group-Club de medecine foetale (2010) Termination of pregnancy following prenatal diagnosis in France: how severe are the foetal anomalies? Prenat Diagn 30:531–539PubMedCrossRef
11.
Zurück zum Zitat Duthie SJ (2010) Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis 34:101–109PubMedCrossRef Duthie SJ (2010) Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis 34:101–109PubMedCrossRef
12.
Zurück zum Zitat Ebbing M, Bonaa KH, Nygard O, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, Njolstad I, Refsum H, Nilsen DW, Tverdal A, Meyer K, Vollset SE (2009) Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 302:2119–2126PubMedCrossRef Ebbing M, Bonaa KH, Nygard O, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, Njolstad I, Refsum H, Nilsen DW, Tverdal A, Meyer K, Vollset SE (2009) Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 302:2119–2126PubMedCrossRef
13.
Zurück zum Zitat Figueiredo JC, Levine AJ, Grau MV, Berry EL, Ueland PM, Ahnen DJ, Byers T, Bresalier RS, Summers RW, Bond J, McKeown-Elyssen GE, Sandler RS, Haile RW, Baron JA (2008) Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels. Cancer Epidemiol Biomark Prev 17:2625–2631CrossRef Figueiredo JC, Levine AJ, Grau MV, Berry EL, Ueland PM, Ahnen DJ, Byers T, Bresalier RS, Summers RW, Bond J, McKeown-Elyssen GE, Sandler RS, Haile RW, Baron JA (2008) Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels. Cancer Epidemiol Biomark Prev 17:2625–2631CrossRef
14.
Zurück zum Zitat Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, Bresalier RS, Burke CA, McKeown-Eyssen GE, Baron JA (2009) Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 101:432–435PubMedCrossRef Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, Bresalier RS, Burke CA, McKeown-Eyssen GE, Baron JA (2009) Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 101:432–435PubMedCrossRef
15.
Zurück zum Zitat Grewal J, Carmichael SL, Song J, Shaw GM (2009) Neural tube defects: an analysis of neighbourhood- and individual-level socio-economic characteristics. Paediatr Perinat Epidemiol 23:116–124PubMedCrossRef Grewal J, Carmichael SL, Song J, Shaw GM (2009) Neural tube defects: an analysis of neighbourhood- and individual-level socio-economic characteristics. Paediatr Perinat Epidemiol 23:116–124PubMedCrossRef
16.
Zurück zum Zitat Grupp SG, Greenberg ML, Ray JG, Busto U, Lanctot KL, Nulman I, Koren G (2011) Pediatric cancer rates after universal folic acid flour fortification in Ontario. J Clin Pharmacol 51:60–65PubMedCrossRef Grupp SG, Greenberg ML, Ray JG, Busto U, Lanctot KL, Nulman I, Koren G (2011) Pediatric cancer rates after universal folic acid flour fortification in Ontario. J Clin Pharmacol 51:60–65PubMedCrossRef
17.
Zurück zum Zitat Hirsch S, Sanchez H, Albala C, de la Maza MP, Barrera G, Lieva L, Bunout D (2009) Colon cancer in Chile before and after the start of the flour fortification program with folic acid. Eur J Gastroenterol Hepatol 21:436–439PubMedCrossRef Hirsch S, Sanchez H, Albala C, de la Maza MP, Barrera G, Lieva L, Bunout D (2009) Colon cancer in Chile before and after the start of the flour fortification program with folic acid. Eur J Gastroenterol Hepatol 21:436–439PubMedCrossRef
18.
Zurück zum Zitat Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY (2001) Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285:2981–2986PubMedCrossRef Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY (2001) Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285:2981–2986PubMedCrossRef
19.
Zurück zum Zitat Kim YI (2008) Folic acid supplementation and cancer risk: point. Cancer Epidemiol Biomark Prev 17:2220–2225CrossRef Kim YI (2008) Folic acid supplementation and cancer risk: point. Cancer Epidemiol Biomark Prev 17:2220–2225CrossRef
20.
Zurück zum Zitat Ly A, Lee H, Chen J, Sie K, Renlund R, Medline A, Sohn KJ, Croxford R, Thompson LU, Kim YI (2011) Effect of maternal and postweaning folic acid supplementation on mammary tumor risk in the offspring. Cancer Res 71:988PubMedCrossRef Ly A, Lee H, Chen J, Sie K, Renlund R, Medline A, Sohn KJ, Croxford R, Thompson LU, Kim YI (2011) Effect of maternal and postweaning folic acid supplementation on mammary tumor risk in the offspring. Cancer Res 71:988PubMedCrossRef
21.
Zurück zum Zitat Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G, Rosenberg IH (2007) A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomark Prev 16:1325–1329CrossRef Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G, Rosenberg IH (2007) A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomark Prev 16:1325–1329CrossRef
22.
Zurück zum Zitat Mason JB, Cole BF, Baron JA, Kim YI, Smith AD (2008) Folic acid fortification and cancer risk. Lancet 371:1335, author reply 1335–6PubMedCrossRef Mason JB, Cole BF, Baron JA, Kim YI, Smith AD (2008) Folic acid fortification and cancer risk. Lancet 371:1335, author reply 1335–6PubMedCrossRef
23.
Zurück zum Zitat Padmanabhan R (2006) Etiology, pathogenesis and prevention of neural tube defects. Congenit Anom Kyoto 46:55–67PubMedCrossRef Padmanabhan R (2006) Etiology, pathogenesis and prevention of neural tube defects. Congenit Anom Kyoto 46:55–67PubMedCrossRef
24.
Zurück zum Zitat Rasmussen MM, Clemmensen D (2010) Folic acid supplementation in pregnant women. Dan Med Bull 57:A4134PubMed Rasmussen MM, Clemmensen D (2010) Folic acid supplementation in pregnant women. Dan Med Bull 57:A4134PubMed
25.
Zurück zum Zitat Ray JG, Meier C, Vermeulen MJ, Boss S, Wyatt PR, Cole DE (2002) Association of neural tube defects and folic acid food fortification in Canada. Lancet 360:2047–2048PubMedCrossRef Ray JG, Meier C, Vermeulen MJ, Boss S, Wyatt PR, Cole DE (2002) Association of neural tube defects and folic acid food fortification in Canada. Lancet 360:2047–2048PubMedCrossRef
26.
Zurück zum Zitat Schwarz EB, Sobota M, Gonzales R, Gerbert G (2008) Computerized counseling for folate knowledge and use: a randomized controlled trial. Am J Prev Med 35:568–571PubMedCrossRef Schwarz EB, Sobota M, Gonzales R, Gerbert G (2008) Computerized counseling for folate knowledge and use: a randomized controlled trial. Am J Prev Med 35:568–571PubMedCrossRef
27.
Zurück zum Zitat Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF, Johnson KA, Johnson C, Buys SS, Hoover RN, Ziegler RG (2006) Folate intake, alcohol use, and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Clin Nutr 83:895–904PubMed Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF, Johnson KA, Johnson C, Buys SS, Hoover RN, Ziegler RG (2006) Folate intake, alcohol use, and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Clin Nutr 83:895–904PubMed
28.
Zurück zum Zitat van den Donk M, Pellis L, Crott JW, van Engeland M, Friderich P, Nagengast FM, van Bergeijk JD, de Boer SY, Mason JB, Kok FJ, Keijer J, Kampman E (2007) Folic acid and vitamin B-12 supplementation does not favorably influence uracil incorporation and promoter methylation in rectal mucosa DNA of subjects with previous colorectal adenomas. J Nutr 137:2114–2120PubMed van den Donk M, Pellis L, Crott JW, van Engeland M, Friderich P, Nagengast FM, van Bergeijk JD, de Boer SY, Mason JB, Kok FJ, Keijer J, Kampman E (2007) Folic acid and vitamin B-12 supplementation does not favorably influence uracil incorporation and promoter methylation in rectal mucosa DNA of subjects with previous colorectal adenomas. J Nutr 137:2114–2120PubMed
29.
Zurück zum Zitat Vieira AR, Castillo Taucher S (2005) Maternal age and neural tube defects: evidence for a greater effect in spina bifida than in anencephaly. Rev Méd Chile 133:62–70PubMedCrossRef Vieira AR, Castillo Taucher S (2005) Maternal age and neural tube defects: evidence for a greater effect in spina bifida than in anencephaly. Rev Méd Chile 133:62–70PubMedCrossRef
30.
Zurück zum Zitat Wilson RD, Johnson JA, Wyatt P, Allen V, Gagnon A, Langlois S, Blight C, Audibert F, Desilets V, Brock JA, Koren G, Goh YI, Nguyen P, Kapur B, Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada and The Motherrisk Program (2007) Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 29:1003–1026PubMed Wilson RD, Johnson JA, Wyatt P, Allen V, Gagnon A, Langlois S, Blight C, Audibert F, Desilets V, Brock JA, Koren G, Goh YI, Nguyen P, Kapur B, Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada and The Motherrisk Program (2007) Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 29:1003–1026PubMed
Metadaten
Titel
Decreased incidence of myelomeningocele at birth: effect of folic acid recommendations or prenatal diagnostics?
verfasst von
Dorte Clemmensen
Mathias Thygesen
Mikkel Mylius Rasmussen
Morten Fenger-Grøn
Olav B. Petersen
Claus Mosdal
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
Child's Nervous System / Ausgabe 11/2011
Print ISSN: 0256-7040
Elektronische ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-011-1473-2

Weitere Artikel der Ausgabe 11/2011

Child's Nervous System 11/2011 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.